GlassScriptPhysician profile
Jill Dickerson
NPI 1730201195
$5,255.09
in general payments reported to CMS, 2019-2025
30 companies · $1,765 in 2025
The $1,765 reported for 2025 was more than what 96% of Medical-Surgical (Clinical Nurse Specialist) providers received nationally (typical 2025 total: $167).
See the full distribution for Medical-Surgical (Clinical Nurse Specialist)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $874 · 2022: $533 · 2023: $881 · 2024: $1,202 · 2025: $1,765.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,177 · Education: $671.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,176.78 |
| Education | $670.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $742.76 | 2021-2025 | Darzalex, Tecvayli, Rybrevant |
| Astrazeneca Pharmaceuticals LP | $602.63 | 2023-2025 | Imfinzi, Imjudo |
| Abbvie INC. | $595.64 | 2024-2025 | |
| Astellas Pharma US INC | $424.81 | 2021-2025 | Padcev, Xospata |
| Genzyme Corporation | $352.59 | 2021-2025 | |
| Lilly USA, LLC | $309.47 | 2021 | |
| Emd Serono, INC. | $262.60 | 2023-2024 | Bavencio |
| Novartis Pharmaceuticals Corporation | $241.89 | 2021-2025 | |
| Pharmacyclics LLC, An Abbvie Company | $229.40 | 2021-2023 | Imbruvica, Epkinly |
| Merck Sharp & Dohme LLC | $154.71 | 2021-2025 | Keytruda, Zerbaxa, Lynparza |
| Seagen INC. | $140.84 | 2021-2023 | Adcetris |
| Pulmonx Corporation | $118.31 | 2023 | Zephyr Endobronchial Valve, Chartis Catheter, Pulmonx Chartis Tablet Console |
| Jazz Pharmaceuticals INC. | $109.50 | 2022-2024 | |
| Gilead Sciences, INC. | $104.58 | 2021-2023 | Trodelvy |
| Eisai INC. | $100.56 | 2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Taiho Oncology, INC. | $92.85 | 2023 | |
| Regeneron Healthcare Solutions, INC. | $91.85 | 2024-2025 | Libtayo, Lynozyfic |
| Sanofi-Aventis U.S. LLC | $87.00 | 2022 | |
| Epizyme, INC. | $79.63 | 2021-2022 | |
| Celgene Corporation | $77.40 | 2021 | |
| Beigene USA, INC. | $75.75 | 2024 | Brukinsa |
| Pfizer INC. | $73.99 | 2025 | |
| Genentech USA, INC. | $34.55 | 2022-2025 | Polivy |
| La Jolla Pharmaceutical Company | $32.60 | 2024 | Giapreza |
| G1 Therapeutics, INC. | $23.12 | 2023 | Cosela |
| Iovance Biotherapeutics, INC. | $21.93 | 2025 | Amtagvi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.36 | 2022 | |
| Amgen INC. | $19.25 | 2024 | Tezspire |
| Glaxosmithkline, LLC. | $17.35 | 2023 | Zejula, Jemperli |
| Acrotech Biopharma INC. | $17.17 | 2025 | Beleodaq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jill Dickerson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.